GlioCure aims to give back hope to patients suffering from glial diseases, and in particular to patients with hard-to-treat brain tumours, such as gliobastoma.
To achieve this goal, GlioCure has brought together a scientific and medical advisory board of international experts with all the necessary skills for translational development to treat and/or cure such diseases.
Our lead product, GC01, is a new generation anti-tumor and neuroprotective peptide, which is currently in the final stages of non-regulatory preclinical development for the treatment of glioblastoma.
Angers, April 13th 2021 - GlioCure transforms into a Limited Liability Company and closes a new round of financing
GlioCure, a preclinical-drug-development company specialized in neuro-oncology, announced today that during a recent combined general meeting, its shareholders ratified transformation of GlioCure into a limited liability company governed by a Board of Directors, and have brought two new shareholders into its capital, bringing its bridge funding to nearly €500,000.